Congenital Disorders of Glycosylation: N-Glycan Profile, Qualitative, Plasma
Full Page View | PDF View
Name
Congenital Disorders of Glycosylation: N-Glycan Profile, Qualitative, Plasma
Synonyms
Carbohydrate Deficient Glycoprotein Syndrome (CDGS), CDG (Congenital Disorders of Glycosylation), Congenital Disorders of Glycosylation (CDG), Glycoprotein Syndrome, N-glycan, N-glycans
Test Code
BNGLY
Indication
Manifestations of CDG range from severe developmental delay and hypotonia with multiple organ system involvement to hypoglycemia and protein-losing enteropathy with normal development. The diagnosis should be considered in all patients with failure to thrive, mental retardation, cerebellar hypoplasia, liver dysfunction, or seizures and stroke-like episodes.
CPT Codes
82373 (x1), 83788 (x1), 84375 (x1)
Turn around time
7 days - 10 days
Additional Specimen Collection/Handling Instructions Required for this Test
Only one specimen type is required for this test: Frozen serum or frozen plasma.

Please provide clinical information.  Click here for the clinical presentation form.
Submit only 1 of the following specimen types
Type Specimen Requirements Specimen Collection and Shipping
SerumIn serum (red top) tube:
Draw 1-5 ml blood
Centrifuge immediately to separate serum and freeze.
Ship frozen sample on dry ice with overnight delivery.
PlasmaIn sodium heparin (green top) tube:
Draw 1-5 ml blood
Centrifuge immediately to separate plasma and freeze.
Ship frozen sample on dry ice with overnight delivery.
Condition Description
Congenital disorders of glycosylation (CDG) comprise a group of multi-system diseases with an extremely variable phenotype. Manifestations range from severe developmental delay and hypotonia with multiple organ system involvement beginning in infancy, to hypoglycemia and protein-losing enteropathy with normal development, or isolated failure to thrive. Type I CDG comprises those disorders in which there are defects that affect the biosynthesis of dolichol-linked oligosaccharides in the cytosol or the endoplasmic reticulum (ER), as well as defects involving the transfer of oligosaccharides onto nascent glycoproteins. Type II CDG comprises all defects of further trimming and elongation of N-linked oligosaccharides in the ER and Golgi.

Serum or plasma N-glycan profile can be used to identify most subtypes of CDG type II, combined type I and type II, and multiple glycosylation disorders, such as various types of COG complex deficiencies (Conservated Oligometric Golgi).

Educational Materials:

References:

Faid, V., F. Chirat, et al. (2007)."A rapid mass spectrometric strategy for the characterization of N-glycan and O-glycan chains in the diagnosis of defects in glycan biosynthesis." Proteomics 7(11): 1800-13.

Mandato, C., L. Brive, et al. (2006). "Cryptogenic liver disease in four children: a novel congenital disorder of glycosylation." Pediatr Res 59(2): 293-8.

Jaeken, J., T. Hennet,  H.H. Freeze, G. Matthijs, (2009) "On the nomenclature of congenital disorders of glycosylation (CDG)." JIMD 31:669-672.
Methodology
N-Glycan chains are firstly released from SDS denaturated serum glycoproteins via PNGase F digestion, and then permethylated. The permethylated N-glycan are measured by matrix-assisted laser desorption/ionization time of light mass spectrometry (MALDI- TOF). The structure of the glycans can be further analyzed by MALDI-TOF/TOF.
Reference Range
Click here for reference ranges.
Detection
Comparing to normal serum or plasma, the changes in the N-glycan structure monitored by MALDI profile are used to identify the associated congenital disorders of glycosylation (CDGs) in patients serum or plasma.
Related Tests
  • Carbohydrate Deficient Transferrin for Congenital Disorders of Glycosylation (BCDGS)
  • N-glycan and Carbohydrate Deficient Transferrin Panel for CDGs (BCDGP)
  • Congenital Disorders of Glycosylation: O-glycan Profile and Quantification (BOGLY)
  • Oligosaccharide and Glycan Screening (OS)
  • Sequencing analysis of individual CDG genes is available.
  • Sequencing analysis of different panels for CDG genes are also available.
  • Custom diagnostic mutation analysis (KM) is available to family members if mutations are identified by targeted mutation testing or sequencing analysis.
  • Prenatal testing is available to adult couples who are confirmed carriers of mutations. Please contact the laboratory genetic counselor to discuss appropriate testing prior to collecting a prenatal specimen.
Special Instructions
Click here for the clinical presentation form.